Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing targeted therapies. The company's mission is to leverage its proprietary extended-release delivery system to provide optimal drug delivery for therapeutic areas with high unmet medical needs. Eupraxia Pharmaceuticals is headquartered in Victoria, British Columbia, Canada.

At the core of Eupraxia's innovation is its proprietary Diffusphere™ technology, a polymer-based micro-sphere platform designed for localized, controlled, and extended drug delivery. The company's pipeline includes two primary clinical development programs: EP-104GI, which is in a Phase 1b/2a trial (RESOLVE trial) for the treatment of eosinophilic esophagitis (EoE), and EP-104IAR, which has completed a Phase 2b clinical trial (SPRINGBOARD) for chronic osteoarthritis pain in the knee.

In recent news, Eupraxia Pharmaceuticals announced the appointment of Dr. Jeymi Tambiah as Chief Medical Officer on May 1, 2026, succeeding Dr. Mark Kowalski. The company also reported positive 36-week data from its Phase 1b/2a RESOLVE trial for EP-104GI in eosinophilic esophagitis, demonstrating significant improvements in symptom response and tissue health. Furthermore, Eupraxia completed a public offering in February 2026, raising approximately US$63.2 million to advance its clinical development programs and for general corporate purposes.

Latest updates

Eupraxia Appoints Seasoned CMO Amid Gastroenterology Pipeline Advancement

Event summary

  • Eupraxia Pharmaceuticals has appointed Dr. Jeymi Tambiah as Chief Medical Officer, effective immediately.
  • The appointment coincides with the retirement of current CMO Dr. Mark Kowalski, who will serve as a senior consultant during the transition.
  • Dr. Tambiah brings over 18 years of experience in clinical development, regulatory strategy, and product commercialization.
  • Eupraxia is currently advancing EP-104GI in a Phase 1b/2 trial (RESOLVE) for the treatment of Eosinophilic Esophagitis (EoE).

The big picture

The appointment of a physician-scientist CMO signals Eupraxia’s focus on advancing its clinical pipeline, particularly EP-104GI for EoE, a condition with significant unmet need. Dr. Tambiah’s experience in immunology and late-stage development suggests a strategy to accelerate regulatory submissions and potentially broaden the application of Eupraxia’s Diffusphere™ technology beyond its current focus.

What we're watching

Clinical Execution
The RESOLVE trial’s data catalysts will be critical in validating EP-104GI’s efficacy and safety profile, and Dr. Tambiah’s experience will be key to navigating potential challenges.
Pipeline Expansion
The stated intention to expand the gastroenterology pipeline beyond EP-104GI will require strategic prioritization and resource allocation under the new CMO’s leadership.
Regulatory Pathway
The success of Eupraxia’s Diffusphere™ technology will depend on its ability to secure regulatory approvals for multiple applications, a process that remains subject to significant uncertainty.
CID: 1014